Millie
your market intelligence analyst
Search Results
439 results
Your search is now limited to «Prostate Cancer» expert search.
ClinicalTrials.gov 05/28/2020 07:12
Additionally, the registry will measure the prevalence and distribution of pathogenic mutations in hereditary cancer risk-associated genes among men with prostate cancer who meet National Cancer Center Network (NCCN) criteria for hereditary cancer genetic testing.
More from ClinicalTrials.gov:
News-Medical.net 05/27/2020 01:43
Furthermore, black men are at increased risk of a prostate cancer diagnosis, and significantly greater risk of dying from prostate cancer compared to whites.
More from News-Medical.net:
PubMed News (NIH) 05/27/2020
Those cell lines represent novel in vitro models of androgen‑dependent and –independent prostate cancer, recapitulating the progression of the disease to a more invasive phenotype upon androgen deprivation.
More from PubMed News (NIH):
These findings suggest that germacrone may potentially contribute to the development of a new therapeutic agent for prostate cancer treatment.
More from International Journal of COPD:
Onclive 05/25/2020 12:30
Decreases in local-stage and increases in distant- and regional-stage prostate cancer incidence could be the result of a recommendation issued by the US Preventive Services Task Force against prostate-specific antigen–based screenings,
More from Onclive:
Thank you for your reply i have to say i have never felt as bad as i was on Thursday i can normally manage the side effects and get past them. I seem to struggle with muscle weakness and tiredness a lot especially when i take my tamoxifen on a Wednesday the next couple of days can be the worst. Thank you once again for all your replies and hope all is going well with your treatments.
More from Macmillan Cancer - Prostate Forum:
Prostate-Specific Antigen The research examined cases diagnosed from 2005 to 2016, a period where federal guidelines warned against a prostate-specific antigen or PSA screening for prostate cancer detection.
More from International Business Times (United Kingdom):
GlobeNewswire 05/22/2020 04:00
In April 2020, CLS obtained EU approval and an EC Certificate for the TRANBERG System, Thermoguide software and related products to be marketed and sold in Europe for indications such as prostate cancer, brain tumors, and epilepsy.
More from GlobeNewswire:
ESMO News (EU) 05/22/2020 03:20
... May 2020, the US Food and Drug Administration (FDA) approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.
More from ESMO News (EU):
Kintor Pharmaceutical, a developer of prostate cancer and hair-loss therapies that just completed one of the hottest biotech initial public offerings in Hong Kong, has lofty ambitions to take on blockbuster drugs in China and the US.The company is conducting phase three clinical trials in mainland for proxalutamide, its top candidate for late-stage prostate cancer treatment.
More from South China Morning Post (China):
These results further establish that genomic testing for HRR mutations should be a critical step for the diagnosis and determination of treatment options for men with advanced prostate cancer.
More from Pharmaceutical Business Review:
Cancer Network 05/21/2020
The persistently increasing regional- and distant-stage prostate cancer incidence during the past 5 years has public health implications given the substantial morbidity and premature mortality associated with it and the recent stabilization of prostate cancer death rates after a steady decline since the ...
More from Cancer Network:
Motley Fool 05/20/2020 16:30
Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option.
More from Motley Fool:
PharmaTimes 05/20/2020 15:21
These results further establish that genomic testing for HRR mutations should be a critical step for the diagnosis and determination of treatment options for men with advanced prostate cancer.
More from PharmaTimes:
DoctorsLounge 05/20/2020 13:00
More information Learn more about prostate cancer screening from the American Cancer Society.
More from DoctorsLounge:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications